Genelux Corporation (GNLX) vs Outlook Therapeutics, Inc. (OTLK)
A side-by-side comparison of Genelux Corporation and Outlook Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GNLX
Genelux Corporation
$2.60HealthcareDelayed quote: Oct 6, 2026, 11:44 AM EDT
OTLK
Outlook Therapeutics, Inc.
$0.59HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — GNLX vs OTLK
growth of $100 · dividends reinvested · last 4yGNLX -57.7% (-19.4%/yr)OTLK -97.3% (-59.5%/yr)GNLX compounded faster over this window
Log scale — wide-divergence pair
GNLX OTLK
GNLX vs OTLK: by the numbers
- •GNLX is the larger company ($117M vs $110M market cap).
- •Both run net losses; OTLK's is the smaller (-4416.22% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | GNLX | OTLK |
|---|---|---|
| P/S ratio | 14573.14 | N/A |
| P/B ratio | 7.24 | N/A |
Profitability
| Metric | GNLX | OTLK |
|---|---|---|
| Gross margin | -7075.00% | 46.49% |
| Operating margin | -415175.00% | -4744.25% |
| Net margin | -422412.50% | -4416.22% |
| ROE | -209.73% | N/A |
| ROIC | -192.18% | -352.19% |
Growth (annualized)
| Metric | GNLX | OTLK |
|---|---|---|
| Total return CAGR (5Y) | N/A | -57.40% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.